Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

First study (n=468) reports no significant difference in asthma exacerbation rate between reslizumab and placebo (rate ratio 0.79, 95% CI 0.56–1.12; p=0.19), and second study showed no difference in reduction of daily oral corticosteroid dose (OR 1.23, 0.70–2.16; p=0.47).

SPS commentary:

Reslizumab is a subcutaneously administered anti-interleukin-5 monoclonal antibody, currently in phase III development for eosinophilic asthma.


The Lancet Respiratory Medicine

Resource links: